THERAPY OF THE POLYCYTHEMIA VERA WITH RUXOLITINIB

Currently, methods of therapeutic the treatment of polycythemia vera (PV) are: prophylaxis of thrombotic complications with acetylsalicylic acid; erythrocytapheresis; cytoreductive therapy; treatment of thrombotic complications; therapy in special conditions (pregnancy, surgery). The first line of the treatment at a young age is interferon α, in the older age group is hydroxycarbamide. In 15-25% of cases, these drugs have low efficiency and poor tolerance. The transition to another line is indicated if the therapy is ineffective or patient is intolerant of the therapy. Results of clinical trials have proved the effectiveness of ruxolitinib, JAK2 inhibitor, in the management of splenomegaly and constitutional symptoms in patients with primary myelofibrosis and PV. A review of the literature and a description of the clinical case of the effective treatment of the PV patient ruxolitinib is presented.

Melikyan A.L., Turkina A.G., Abdulkadyrov K.M., Zarickij A.YU., Afanas’ev B.V., SHuvaev V.A. et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (true polycythemia, essential thrombocythemia, primary myelofibrosis). Russian Journal of Hematology and Transfusiology (Gematologiya i transfusiologiya). 2014; 59(4): 31-56. (in Russian)

Melikyan A.L., Suborceva I.N. Myeloproliferative neoplasms: new data. Russian Journal of Clinical oncohematology. Fundamental research and clinical practice (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2016; 9(2): 218-28. (in Russian)

Mehta J., Wang H., Iqbal S.U., Mesa R. Epidemiology of myeloprolifera-tivevneoplasms in the United States. Leuk. Lymphoma. 2014; 55(3): 595-600.

Saliba J., Saint-Martin C., Di Stefano A., Lenglet G., Marty C., Keren B., et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat. Genet. 2015; 47(10): 1131-40.

Melikyan A.L., Suborceva I.N. Materials of the 58th Congress of the American Hematology Society (December 2016, San Diego). Russian Journal of Clinical Oncohematology. Fundamental research and clinical practice (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2017; 10(2): 258-70. (in Russian)

Tefferi A., Rumi E., Finazzi G., Gisslinger H., Vannucchi A.M., Rodeghiero F., Randi M.L., et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013; 27(9): 1874-81.

Marchioli R., Finazzi G., Landolfi R., Kutti J., Gisslinger H., Patrono C., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol. 2005; 23(10): 2224-32.

Melikyan A.L., Suborceva I.N. Materials of the 19th Congress of the European Hematology Association (2014, Milan). Russian Journal of Clinical Oncohematology. Fundamental research and clinical practice (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2014; 7(4): 598-607. (in Russian).

Melikyan A.L., Suborceva I.N. Materials of the 56th Congress of the American Hematology Society (December 2014, San Francisco). Russian Journal of Clinical Oncohematology. Fundamental research and clinical practice (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2015; 8(2): 201-32. (in Russian)

Subortseva I.N., Kolosheynova T.I., Pustovaya E.I., Egorova E.K., Kovrigina A.M., Pliskunova Yu.V., et al. Polycythemia vera: a review of literature and our own data. Russian Journal of Clinical Oncohematology. Fundamental research and clinical practice (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2015; 8(4): 397-412. (in Russian)

Subortseva I.N., Kolosheinova T.I., Pustovaya E.I., Egorova E.K., Kovrigina A.M., Pliskunova Yu.V., et al. Diagnosis and treatment of polycythemia vera (PV) in Russian Federation: single center experience. Blood. 2015; 126(23): 5196.

Emanuel R.M., Dueck A.C., Geyer H.L., Kiladjian J.J., Slot S., Zweegman S., et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J. Clin. Oncol. 2012; 30(33): 4098-103.

Tefferi A., Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin. Thromb. Hemost. 2007; 33(4): 313-20.

Marchioli R., Finazzi G., Specchia G., Cacciola R., Cavazzina R., Cilloni D., et al.; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 2013; 368(1): 22-33.

Kremyanskaya M., Mascarenhas J., Hoffman R. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. Expert. Opin. Pharmacother. 2015; 16(8): 1185-94.

Landolfi R., Marchioli R. European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Semin. Thromb. Hemost. 1997; 23(5): 473-8.

Landolfi R., Marchioli R., Kutti J., Gisslinger H., Tognoni G., Patrono C., Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 2004; 350(2): 114-24.

Suborceva I.N., Melikyan A.L., Kovrigina A.M., Sudarikov A.B. Latent polycythemia vera. Russian Journal of Hematology and transfusiology (Gematologiya i transfusiologiya). 2016; 61(1, Suppl. 1): 72. (in Russian)

Silver R.T. Long-Term effects of the treatment of polycythemia vera with recombinant IFNα. Cancer. 2006; 107(3): 451-8.

Najean Y. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997; 90(9): 3370-7.

Cortelazzo S., Finazzi G., Ruggeri M. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 1995; 332(17): 1132-6.

Quintas-Cardama A., Kantarjian H., Manshouri T., Luthra R., Estrov Z., Pierce S., et al. Pegylated interferon α2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol. 2009; 27(32): 5418-24.

Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia. 2008; 22(1): 3-13. doi:10.1038/sj.leu.2404946

Melikyan A.L., Subortseva I.N. Biology of myeloproliferative diseases. Russian Journal of Clinical Oncohematology. Fundamental research and clinical practice (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2016; 9(3): 314-25. doi: 10.1182/blood-2009-03-209262. (in Russian)

Quintas-Cardama A., Vaddi K., Liu P., Vestri O., Galli M., Rodeghiero F., Barbui T. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115(15): 3109-17.

Vannucchi A.M., Kiladjian J.J., Griesshammer M., Masszi T., Durrant S., Passamonti F., et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 2015; 372(5): 426-35.

Cervantes F., Vannucchi A.M., Kiladjian J.J., Al-Ali H.K., Sirulnik A., Stalbovskaya V., et al.; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25): 4047-53.

Mesa R., Vannucchi A.M., Yacoub A., Zachee P., Garg M., Lyons R., et al. The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br. J. Haematol. 2017; 176(1): 76-85. doi:10.1111/bjh.14382.

Alvarez-Larrán A., Kerguelen A., Hernández-Boluda J.C., Pérez-Encinas M., Ferrer-Marín F., Bárez A., et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br. J. Haematol. 2016; 172(5): 786-93.

Antonioli E., Guglielmelli P., Pieri L., Finazzi M., Rumi E., Martinelli V., et al. Hydroxyurea-related toxicity in 3,411 patients with Ph-negative MPN. Am. J. Hematol. 2012; 87(5): 552-4.

Instructions for the use of the drug Jakavi® No. LP 002028, issued by the Ministry of Health of the Russian Federation of 21.03.2013. Available at: https://www.rlsnet.ru/tn_index_id_58405.htm (Access 06 Apr 2017)

Bjorkholm M., Derolf A.R., Hultcrantz M., Kristinsson S.Y., Ekstrand C., Goldin L.R., et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J. Clin. Oncol. 2011; 29(17): 2410-5.

Verstovsek S., Vannucchi A.M., Griesshammer M., Masszi T., Durrant S., Passamonti F., et al. Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 Week follow up from the RESPONSE trial. Haematologica. 2016; 101(7): 821-9. doi: 10.3324/haematol.2016.143644

Tanashyan M.M., Kuznecova P.I., Lagoda O.V., SHabalina A.A., Suborceva I.N., Melikyan A.L. Myeloproliferative diseases and ischemic stroke. Annals of clinical and experimental neurology. Russian Journal (Annaly klinicheskoy i eksperimentalnoy nevrologii). 2014; 8(2): 41-5. (in Russian)

Melikyan A.L., Subortceva I.N., Suhanova G.A. Thrombohemorrhagic complications in patients with Ph-negative myeloproliferative diseases. Russian Journal “Blood” (Krov’). 2014; 2(1): 21-5. (in Russian)

Samuelson B.T., Vesely S.K., Chai-Adisaksopha C., Scott B.L., Crowther M., Garcia D. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul. Fibrinolysis. 2016; 27(6): 648-52. doi: 10.1097/MBC.0000000000000446.